Revenue Cycle Management Leader Helps Evolve Reimbursement Practices that Support Personalized Medicine
San Diego, CA — November 2, 2010 -- XIFIN Inc., the leading provider of revenue cycle management for diagnostic service providers, announced the signing of several new contracts serving the molecular diagnostics market, including LineaGen Inc., Signal Genetics and Veracyte, Inc. The companies will use XIFIN’Âs revenue cycle management services to manage their billing and claims management needs and monitor revenue cycle and financial performance.
"Molecular diagnostics (MDx) laboratories are on the cutting edge of a new patient care paradigm, and we are proud to join them at the forefront of the move toward targeted healthcare delivery," stated Lâle White, CEO of XIFIN. "Through the review and analysis of third party claims data, revenue cycle management systems will be critical tools for MDx companies seeking to demonstrate clinical utility and ensure value-added reimbursement."
LineaGen Inc., of Salt Lake City, UT, focuses on complex disorders and diseases for which early diagnosis and intervention can significantly improve outcome, and has discovered genetic factors associated with autism, multiple sclerosis and chronic obstructive pulmonary disease through its unique genetic research expertise and proprietary molecular diagnostics.
Signal Genetics, headquartered in New York, NY, is a predictive genetic testing company focused on supplying cancer patients with a correlated predictive outcome of disease stage, odds of relapse and a guide to the optimal treatment regimen based on their specific genetic expression profile.
Veracyte, Inc., based in South San Francisco, CA, is pioneering the emerging field of molecular cytology, applying molecular biomarkers to cytology samples in order to improve cancer diagnosis by clarifying indeterminate results obtained from current methods.
XIFIN recently published a white paper entitled, "A CEO's Guide to Molecular Diagnostic Reimbursement: Navigating the Many Challenges of Reimbursement and Commercialization" written by industry expert Rina Wolf, VP of Commercialization Strategies, Consulting and Industry Affairs at XIFIN, Inc. to promote discussion and educate the market on issues impacting molecular diagnostic testing and reimbursement.
XIFIN has processed more than 150 million claims for a variety of diagnostic service providers across various healthcare segments including clinical, hospital outreach, anatomic pathology, molecular diagnostics, therapeutic pain management, radiology and more.